Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies

ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

Authors: Anagnostis P, Bosdou JK, Vaitsi K, Goulis DG, Lambrinoudaki I Abstract Menopausal hormone therapy (MHT) is effective in preventing menopause-related bone loss and decreasing vertebral, non-vertebral and hip fracture risk. MHT contains estrogens that exert both antiosteoclastic and osteoanabolic effects. These effects are dose-dependent, as even ultra-low doses preserve or increase bone mineral density. The transdermal route of administration is effective on cancellous and cortical bone, although fracture data are still lacking. Hormone replacement therapy is the treatment of choice to preserve skeletal hea...
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Can women in menopause get the benefits of hormone replacement therapy without the risks? Anew UCLA study conducted with mice points in that direction, but additional research is necessary.Women commonly experience hot flashes and weight gain, among other changes, during and after menopause. Hormone therapy, which gives women additional estrogen, can help alleviate some of these symptoms, but it has been linked to a higher risk of heart disease and breast cancer.UCLA life scientists now report that a gene called reprimo, which is expressed by certain neurons in the brain, may play a role in menopause-related weight gain, a...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Excess body weight is an established risk factor for breast cancer. Research suggests that’s because too much body fat can elevate levels of sex hormones like estrogen, especially among postmenopausal women. But despite knowing there is a correlation between extra weight and breast cancer, it’s been difficult to study how losing that weight could affect an individual woman’s chance of developing cancer. Now, a new paper published in the Journal of the National Cancer Institute provides encouraging evidence that, for women 50 and older, virtually any amount of sustained weight loss translates to a reductio...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer embargoed study Source Type: news
Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Conclusions: Decisions regarding the use of HT in women who undergo BSO after detection of a BRCA mutation must be individualized based on careful consideration of the risks and benefits. However, the risks of a subsequent cancer diagnosis appear small, particularly in regards to the benefits of treatment afforded by HT.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
The pendulum has swung from one extreme to the other when it comes to hormone replacement therapy (HRT) to treat symptoms of menopause. At first, the replacement hormones—mostly a combination of estrogen and progestin to replace what the body stops making after menopause—were seen as a panacea. Doctors thought they could not only relieve hot flashes and night sweats, but also prevent chronic aging diseases like heart problems and weakening bones. But studies then found that the supplement hormones could lead to a higher risk of breast cancer—and that they didn’t protect the heart after all. In the l...
Source: TIME.com: Top Science and Health Stories - Category: Consumer Health News Authors: Tags: Uncategorized Drugs estrogen Hormone Therapy hormones for menopause hot flashes night sweats progestin Reproductive Health treating menopause Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Epidemiology | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Study